Axiom Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Axiom Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73	Buy	+20	New	+$67	﹤0.01%	513

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Axiom Investment Management's RXRX Position: Q2 2026 in Review

Axiom Investment Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 20 shares worth $73. The stake represents ﹤0.01% of the portfolio and ranks #513 among its holdings.

192 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Axiom Investment Management held 20 shares of Recursion Pharmaceuticals worth $73 as of Q2 2026.
Recursion Pharmaceuticals was a new Axiom Investment Management position in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Axiom Investment Management's portfolio in Q2 2026, its #513 holding.
192 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Axiom Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.